Features of BOOSTRIX®

Dose and Schedule"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

  • BOOSTRIX is administered as a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
  • There are no data to support repeat administration of BOOSTRIX
  • Five years should elapse between the last dose of the recommended series of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) and/or Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) vaccine and the administration of BOOSTRIX


BOOSTRIX is available in Tip-Lok® syringes"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

  • Single unit-dose prefilled for your convenience*
  • Same cost per dose as vials
  • Luer-Lok® adapter fits virtually any needle
  • The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
* Each syringe delivers the labeled dose.


BOOSTRIX comes with a 2D barcode

  • 2D barcodes contain the vaccine name, manufacturer, National Drug Code (NDC) numbers, lot number, and expiration date
  • With 2D barcodes, you can update your inventory management system, patient records, and vaccination reports automatically, reducing the need for manual data entry if you have the correct scanner, hardware, and software


Preparation for Administration"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1

  • Shake vigorously to obtain a homogeneous, turbid, white suspension before administration. Do not use if resuspension does not occur with vigorous shaking. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered
  • For the prefilled syringes, attach a sterile needle and administer intramuscularly
  • For the vials, use a sterile needle and sterile syringe to withdraw the 0.5-mL dose and administer intramuscularly. Changing needles between drawing vaccine from a vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated. Use a separate sterile needle and syringe for each individual
  • Do not administer this product intravenously, intradermally, or subcutaneously


CPT® code5 : 90715

  • BOOSTRIX and Tip-Lok are registered trademarks of the GSK group of companies.
  • Luer-Lok is a registered trademark of Becton, Dickinson and Company.
  • CPT is a registered trademark of the American Medical Association.

Indication for BOOSTRIX

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.

Important Safety Information for BOOSTRIX

  • Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
  • Prior to administration, review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions to assess benefits and risk. Epinephrine and other appropriate agents used for control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur
  • The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
  • The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
  • Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • In clinical studies, common adverse reactions were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, gastrointestinal symptoms, and fever
  • Vaccination with BOOSTRIX may not result in protection in all vaccine recipients


"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

BOOWCNT190004 June 2019